Drug Database · Clinicians

Tigecycline

Brands (16) Tigecid, Tygacil, Clyntigex…Show all

Tetracycline-class Antibacterial US FDA class
Antibacterial (tetracycline) PH FDA category

No kidney change; not dialyzableRx · Prescription drug19 PH products Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 2ccdb48e-c14a-4eeb-348c-4920ccfd7465, version date November 18, 2025 (Tygacil · Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Complicated skin and skin structure infections
  • Complicated intra-abdominal infections
  • Community-acquired bacterial pneumonia
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE TYGACIL is a tetracycline class antibacterial indicated in patients 18 years of age and older for:

  • Complicated skin and skin structure infections (1.1)
  • Complicated intra-abdominal infections (1.2)
  • Community-acquired bacterial pneumonia (1.3) Limitations of Use: TYGACIL is not indicated for treatment of diabetic foot infection or hospital-acquired pneumonia, including ventilator-associated pneumonia (1.4). To reduce the development of drug-resistant bacteria and maintain the effectiveness of TYGACIL and other antibacterial drugs, TYGACIL should be used only to treat infections that are proven or strongly suspected to be caused by bacteria (1.5). 1.1 Complicated Skin and Skin Structure Infections TYGACIL is indicated in patients 18 years of age and older for the treatment of complicated skin and skin structure infections caused by susceptible isolates of Escherichia coli, Enterococcus faecalis (vancomycin-susceptible isolates), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus agalactiae, Streptococcus anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus), Streptococcus pyogenes, Enterobacter cloacae, Klebsiella pneumoniae, and Bacteroides fragilis. 1.2 Complicated Intra-abdominal Infections TYGACIL is indicated in patients 18 years of age and older for the treatment of complicated intra-abdominal infections caused by susceptible isolates of Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Enterococcus faecalis (vancomycin-susceptible isolates), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus), Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Clostridium perfringens, and Peptostreptococcus micros. 1.3 Community-Acquired Bacterial Pneumonia TYGACIL is indicated in patients 18 years of age and older for the treatment of community-acquired bacterial pneumonia caused by susceptible isolates of Streptococcus pneumoniae (penicillin-susceptible isolates), including cases with concurrent bacteremia, Haemophilus influenzae, and Legionella pneumophila. 1.4 Limitations of Use TYGACIL is not indicated for the treatment of diabetic foot infections. A clinical trial failed to demonstrate non-inferiority of TYGACIL for treatment of diabetic foot infections. TYGACIL is not indicated for the treatment of hospital-acquired or ventilator-associated pneumonia. In a comparative clinical trial, greater mortality and decreased efficacy were reported in TYGACIL-treated patients [see Warnings and Precautions (5.2)]. 1.5 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of TYGACIL and other antibacterial drugs, TYGACIL should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify the causative organisms and to determine their susceptibility to tigecycline. TYGACIL may be initiated as empiric monotherapy before results of these tests are known.

Contraindications

  • Known hypersensitivity to tigecycline or excipients
renalcarematters.com, reviewed
Contraindications (US label) US FDA label

4 CONTRAINDICATIONS TYGACIL is contraindicated for use in patients who have known hypersensitivity to tigecycline or to any of the excipients. Reactions have included anaphylactic reactions [see Warnings and Precautions (5.3) and Adverse Reactions (6.2)]. • Known hypersensitivity to tigecycline. (4)

Dosing: Adult

  • Adults: 100 mg IV loading dose, then 50 mg every 12 hours (infuse over 30 to 60 minutes)
  • Severe hepatic impairment (Child-Pugh C): 100 mg, then 25 mg every 12 hours
renalcarematters.com, reviewed
Dosage and administration (US label) US FDA label
  • • Initial dose of 100 mg followed by 50 mg every 12 hours administered intravenously over approximately 30 to 60 minutes. (2.1)
  • • Severe hepatic impairment (Child Pugh C): Initial dose of 100 mg followed by 25 mg every 12 hours. (2.2)
  • • Obtain baseline blood coagulation parameters, including fibrinogen, and continue to monitor regularly during treatment with TYGACIL. (2.4, 5.6)
2.1 Recommended Adult Dosage

2.1 Recommended Adult Dosage The recommended dosage regimen for TYGACIL is an initial dose of 100 mg, followed by 50 mg every 12 hours. Intravenous infusions of TYGACIL should be administered over approximately 30 to 60 minutes every 12 hours. The recommended duration of treatment with TYGACIL for complicated skin and skin structure infections or for complicated intra-abdominal infections is 5 to 14 days.

The recommended duration of treatment with TYGACIL for community-acquired bacterial pneumonia is 7 to 14 days. The duration of therapy should be guided by the severity and site of the infection and the patient's clinical and bacteriological progress.

2.2 Dosage in Patients With Hepatic Impairment

2.2 Dosage in Patients With Hepatic Impairment No dosage adjustment is warranted in patients with mild to moderate hepatic impairment (Child Pugh A and Child Pugh B). In patients with severe hepatic impairment (Child Pugh C), the initial dose of TYGACIL should be 100 mg followed by a reduced maintenance dose of 25 mg every 12 hours.

Patients with severe hepatic impairment (Child Pugh C) should be treated with caution and monitored for treatment response [see Clinical Pharmacology (12.3) and Use in Specific Populations (8.6)].

2.3 Dosage in Pediatric Patients

2.3 Dosage in Pediatric Patients The safety and efficacy of the proposed pediatric dosing regimens have not been evaluated due to the observed increase in mortality associated with TYGACIL in adult patients. Avoid use of TYGACIL in pediatric patients unless no alternative antibacterial drugs are available. Under these circumstances, the following doses are suggested:

  • Pediatric patients aged 8 to 11 years should receive 1.2 mg/kg of TYGACIL every 12 hours intravenously to a maximum dose of 50 mg of TYGACIL every 12 hours.
  • Pediatric patients aged 12 to 17 years should receive 50 mg of TYGACIL every 12 hours. The proposed pediatric doses of TYGACIL were chosen based on exposures observed in pharmacokinetic trials, which included small numbers of pediatric patients [see Use in Specific Populations (8.4) and Clinical Pharmacology (12.3)]. There are no data to provide dosing recommendations in pediatric patients with hepatic impairment.
2.4 Monitoring of Blood Coagulation Parameters

2.4 Monitoring of Blood Coagulation Parameters Obtain baseline blood coagulation parameters, including fibrinogen, and continue to monitor regularly during treatment with TYGACIL [see Warnings and Precautions (5.6)].

2.5 Preparation and Administration

2.5 Preparation and Administration Each vial of TYGACIL should be reconstituted with 5.3 mL of 0.9% Sodium Chloride Injection, USP, 5% Dextrose Injection, USP, or Lactated Ringer's Injection, USP to achieve a concentration of 10 mg/mL of tigecycline. (Note: Each vial contains a 6% overage. Thus, 5 mL of reconstituted solution is equivalent to 50 mg of the drug.) The vial should be gently swirled until the drug dissolves.

Reconstituted solution must be transferred and further diluted for intravenous infusion. Withdraw 5 mL of the reconstituted solution from the vial and add to a 100 mL intravenous bag for infusion (for a 100 mg dose, reconstitute two vials; for a 50 mg dose, reconstitute one vial). The maximum concentration in the intravenous bag should be 1 mg/mL.

The reconstituted solution should be yellow to orange in color; if not, the solution should be discarded. Parenteral drug products should be inspected visually for particulate matter and discoloration (e.g., green or black) prior to administration. Once reconstituted, TYGACIL may be stored at room temperature (not to exceed 25°C/77°F) for up to 24 hours (up to 6 hours in the vial and the remaining time in the intravenous bag).

If the storage conditions exceed 25°C (77°F) after reconstitution, tigecycline should be used immediately. Alternatively, TYGACIL mixed with 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP may be stored refrigerated at 2° to 8°C (36° to 46°F) for up to 48 hours following immediate transfer of the reconstituted solution into the intravenous bag.

TYGACIL may be administered intravenously through a dedicated line or through a Y-site. If the same intravenous line is used for sequential infusion of several drugs, the line should be flushed before and after infusion of TYGACIL with 0.9% Sodium Chloride Injection, USP, 5% Dextrose Injection, USP or Lactated Ringer's Injection, USP.

Injection should be made with an infusion solution compatible with tigecycline and with any other drug(s) administered via this common line.

2.6 Drug Compatibilities

2.6 Drug Compatibilities Compatible intravenous solutions include 0.9% Sodium Chloride Injection, USP, 5% Dextrose Injection, USP, and Lactated Ringer's Injection, USP. When administered through a Y-site, TYGACIL is compatible with the following drugs or diluents when used with either 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP: amikacin, dobutamine, dopamine HCl, gentamicin, haloperidol, Lactated Ringer's, lidocaine HCl, metoclopramide, morphine, norepinephrine, piperacillin/tazobactam (EDTA formulation), potassium chloride, propofol, ranitidine HCl, theophylline, and tobramycin.

2.7 Drug Incompatibilities

2.7 Drug Incompatibilities The following drugs should not be administered simultaneously through the same Y-site as TYGACIL: amphotericin B, amphotericin B lipid complex, diazepam, esomeprazole, and omeprazole.

Dosing: Altered kidney function

Tigecycline is eliminated mainly in bile; about 22% of a dose appears unchanged in urine. The US label needs no dose change in kidney impairment or on hemodialysis, which does not remove it. Severe liver impairment (Child-Pugh C) needs a lower maintenance dose, and the label carries a boxed warning on higher all-cause mortality.

Kidney function measure: Label PK uses CrCl (mL/min); no dose bands.

Show full dosing details
CrCl ≥60 mL/min
No dose change in kidney impairment (label).
CrCl 30–59 mL/min
No dose change in kidney impairment (label).
CrCl 15–29 mL/min
No dose change in kidney impairment (label).
CrCl <15 mL/min (not on dialysis)
No dose change in kidney impairment (label).
Hemodialysis (intermittent)
No dose change; not removed by hemodialysis (label).
Peritoneal dialysis
No peritoneal dialysis data in label. The label needs no change in kidney impairment or hemodialysis. For PD-associated peritonitis (ISPD 2022, systemic): IV 100 mg loading dose, then 50 mg every 12 hours (Table 6).
CRRT
Not in label. Li 2020 (Table 3): no change in CVVH, CVVHD or CVVHDF.
  • Dialyzable? No: not removed in significant quantities by hemodialysis (label). Protein binding 71% to 89%.
  • Monitoring Coagulation tests including fibrinogen at baseline and regularly; liver tests; pancreatitis symptoms (label).
Children (kidney dosing)
eGFR ≥60
Not recommended under 18 years (safety not established; reserved for no-alternative situations) (label). Kidney dosing not applicable.
eGFR 30–59
Not recommended under 18 years (safety not established; reserved for no-alternative situations) (label). Kidney dosing not applicable.
eGFR 15–29
Not recommended under 18 years (safety not established; reserved for no-alternative situations) (label). Kidney dosing not applicable.
eGFR <15 (not on dialysis)
Not recommended under 18 years (safety not established; reserved for no-alternative situations) (label). Kidney dosing not applicable.
Hemodialysis (intermittent)
Not recommended under 18 years (safety not established; reserved for no-alternative situations) (label). Kidney dosing not applicable.
Peritoneal dialysis
Not recommended under 18 years (safety not established; reserved for no-alternative situations) (label). Kidney dosing not applicable.
CRRT
Not recommended under 18 years (safety not established; reserved for no-alternative situations) (label). Kidney dosing not applicable.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

US label text: Renal impairment US FDA label

Renal Impairment A single dose study compared 6 subjects with severe renal impairment (creatinine clearance <30 mL/min), 4 end stage renal disease (ESRD) patients receiving tigecycline 2 hours before hemodialysis, 4 ESRD patients receiving tigecycline 1 hour after hemodialysis, and 6 healthy control subjects. The pharmacokinetic profile of tigecycline was not significantly altered in any of the renally impaired patient groups, nor was tigecycline removed by hemodialysis. No dosage adjustment of TYGACIL is necessary in patients with renal impairment or in patients undergoing hemodialysis.

Dosing: Hepatic impairment

8.6 Hepatic Impairment No dosage adjustment is warranted in patients with mild to moderate hepatic impairment (Child Pugh A and Child Pugh B). In patients with severe hepatic impairment (Child Pugh C), the initial dose of tigecycline should be 100 mg followed by a reduced maintenance dose of 25 mg every 12 hours. Patients with severe hepatic impairment (Child Pugh C) should be treated with caution and monitored for treatment response [see Clinical Pharmacology (12.3) and Dosage and Administration (2.2)].

2.2 Dosage in Patients With Hepatic Impairment No dosage adjustment is warranted in patients with mild to moderate hepatic impairment (Child Pugh A and Child Pugh B). In patients with severe hepatic impairment (Child Pugh C), the initial dose of TYGACIL should be 100 mg followed by a reduced maintenance dose of 25 mg every 12 hours. Patients with severe hepatic impairment (Child Pugh C) should be treated with caution and monitored for treatment response [see Clinical Pharmacology (12.3) and Use in Specific Populations (8.6)].

US FDA label

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use Use in patients under 18 years of age is not recommended. Safety and effectiveness in pediatric patients below the age of 18 years have not been established. Because of the increased mortality observed in TYGACIL-treated adult patients in clinical trials, pediatric trials of TYGACIL to evaluate the safety and efficacy of TYGACIL were not conducted.

In situations where there are no other alternative antibacterial drugs, dosing has been proposed for pediatric patients 8 to 17 years of age based on data from pediatric pharmacokinetic studies [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)]. Because of effects on tooth development, use in patients under 8 years of age is not recommended [see Warnings and Precautions (5.7)].

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Of the total number of subjects who received TYGACIL in Phase 3 clinical studies (n=2514), 664 were 65 and over, while 288 were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, but greater sensitivity to adverse events of some older individuals cannot be ruled out. No significant difference in tigecycline exposure was observed between healthy elderly subjects and younger subjects following a single 100 mg dose of tigecycline [see Clinical Pharmacology (12.3)].

Administration

2.5 Preparation and Administration Each vial of TYGACIL should be reconstituted with 5.3 mL of 0.9% Sodium Chloride Injection, USP, 5% Dextrose Injection, USP, or Lactated Ringer's Injection, USP to achieve a concentration of 10 mg/mL of tigecycline. (Note: Each vial contains a 6% overage. Thus, 5 mL of reconstituted solution is equivalent to 50 mg of the drug.) The vial should be gently swirled until the drug dissolves. Reconstituted solution must be transferred and further diluted for intravenous infusion. Withdraw 5 mL of the reconstituted solution from the vial and add to a 100 mL intravenous bag for infusion (for a 100 mg dose, reconstitute two vials; for a 50 mg dose, reconstitute one vial). The maximum concentration in the intravenous bag should be 1 mg/mL. The reconstituted solution should be yellow to orange in color; if not, the solution should be discarded. Parenteral drug products should be inspected visually for particulate matter and discoloration (e.g., green or black) prior to administration. Once reconstituted, TYGACIL may be stored at room temperature (not to exceed 25°C/77°F) for up to 24 hours (up to 6 hours in the vial and the remaining time in the intravenous bag). If the storage conditions exceed 25°C (77°F) after reconstitution, tigecycline should be used immediately. Alternatively, TYGACIL mixed with 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP may be stored refrigerated at 2° to 8°C (36° to 46°F) for up to 48 hours following immediate transfer of the reconstituted solution into the intravenous bag. TYGACIL may be administered intravenously through a dedicated line or through a Y-site. If the same intravenous line is used for sequential infusion of several drugs, the line should be flushed before and after infusion of TYGACIL with 0.9% Sodium Chloride Injection, USP, 5% Dextrose Injection, USP or Lactated Ringer's Injection, USP. Injection should be made with an infusion solution compatible with tigecycline and with any other drug(s) administered via this common line.

2.6 Drug Compatibilities Compatible intravenous solutions include 0.9% Sodium Chloride Injection, USP, 5% Dextrose Injection, USP, and Lactated Ringer's Injection, USP. When administered through a Y-site, TYGACIL is compatible with the following drugs or diluents when used with either 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP: amikacin, dobutamine, dopamine HCl, gentamicin, haloperidol, Lactated Ringer's, lidocaine HCl, metoclopramide, morphine, norepinephrine, piperacillin/tazobactam (EDTA formulation), potassium chloride, propofol, ranitidine HCl, theophylline, and tobramycin.

2.7 Drug Incompatibilities The following drugs should not be administered simultaneously through the same Y-site as TYGACIL: amphotericin B, amphotericin B lipid complex, diazepam, esomeprazole, and omeprazole.

US FDA label

Dosage forms

Philippines

  • Lyophilized powder for injection: 50 mg
  • Lyophilized powder for injection for i.v. infusion: 50 mg
  • Lyophilized powder for solution for i.v. infusion: 50 mg
  • Lyophilized powder for injection for intravenous: 50 mg
  • Lyophilized powder for injection for intravenous infusion: 50 mg
  • Lyophilized powder for intravenous infusion: 50 mg

Registered products in the Philippines

19 products registered with the Food and Drug Administration (FDA) Philippines list Tigecycline as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products19
Philippine FDA-registered products for Tigecycline
Package insert
ClyntigexTigecycline
50 mg Lyophilized Powder For Injection (IV)5 mL USP Type I Tubular Glass Vial (Box of 1's)
Rx
Lyka Labs LimitedIndia
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-6141-02
May 6, 2030
ImatigTigecycline
50 mg Lyophilized Powder for Intravenous Infusion5 mL Flint Tubular USP Type I Glass Vial (Box of 1's)
Rx
Gufic Biosciences LimitedIndia
Philcare Pharma Inc.Importer: SRS Life Sciences Inc.
DR-XY43501
Jun 26, 2029
IvtigTigecycline
50 mg Lyophilized Powder for Injection (IV Infusion)USP Type I Tubular Glass Vial x 5 mL (Box of 1's)
Rx
Gufic Biosciences LimitedIndia
Option One EnterpriseImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-6144
May 11, 2030
noneTigecycline
50 mg Lyophilized Powder for Injection for I.V. InfusionUSP Type I clear glass vial x 10 mL with butyl rubber stopper, aluminum seal, and flip-off cap (Box of 1's)
Rx
Gufic Biosciences LimitedIndia
Medethix, Inc.
DRP-15379
Jun 28, 2029
SaphcyclineTigecycline
50 mg Lyophilized Powder for Injection (I.V. Infusion)USP Type I clear glass vial X 5 mL with grey bromobutyl rubber stopper and aluminum flip-off seal (Box of l’s and 10's)
Rx
Kilitch Drugs (India) Ltd.India
Nelpa Lifesciences, Inc.
DRP-12161
Jun 29, 2027
Tige-DTigecycline
50 mg Lyophilized Powder for Injection for Intravenous (IV Infusion)USP Type I Clear Glass Vial x 10 mL (Box of 1's)
Rx
Gufic Biosciences LimitedIndia
Rad Medical Distribution Inc.Importer: Medethix, Inc.
DRP-12819-01
Oct 10, 2027
TigecTigecycline
50 mg Lyophilized Powder for Injection (IV)5 mL USP Type I Tubular Glass Vial Box of 1's
Rx
Lyka Labs Ltd.India
Option One EnterpriseImporter: Ambica International Corporation
DRP-6141-01
May 6, 2030
TigecareTigecycline
50mg Lyophilized Powder for Injection (I.V. Infusion)5 mL-Capacity USP Type I Clear and Colorless Glass Vial with Bromobutyl Rubber Stopper and Aluminum Seal with Light Blue Colored Polypropylene Flip-Off Cap (Box of 1's)
Rx
Gland Pharma LimitedIndia
Biocare Lifesciences, Inc.
DRP-11649
Apr 6, 2027
TigecidTigecycline
50 mg Lyophilized Powder for Injection for 1.V. InfusionType I Colorless Glass Vial with Grey Bromobutyl Rubber Stopper and Aluminum Green Propylene Flip off Cap (Box of 10's)
Rx
Centurion İlaç Sanayi Ve Ticaret A.Ş. Ankara ŞubesiTurkey
Stangen Pharmaceuticals Philippines Inc.
DRP-12293
Jul 8, 2027
TigecidTigecycline
50 mg Lyophilized Powder for Injection for I.V. InfusionType I colorless glass vial with bromo butyl rubber stopper and aluminium/propylene flip-off green cap x (Box of 10's)
Rx
Centurion Ilac Sanayi Ve Ticaret A.S.Turkey
Stangen Pharmaceuticals Philippines Inc.
DRP-11143
Feb 7, 2027
TigeclinTigecycline
50 mg Lyophilized Powder for Injection (IV Infusion)10 mL Type I Clear Tubular Glass Vial with Gray Bromobutyl Rubber Stopper and Orange Aluminum Flip-Off Seal Cap x 1's (Box of 1's)
Rx
Gufic Lifesciences Private LimitedIndia
Sun Pharma Philippines, Inc.
DRP-12698
Sep 23, 2027
TigenzaTigecycline
50 mg Lyophilized Powder for Injection (IV Infusion)5 mL Type I clear glass vial with butyl rubber stopper, aluminum seal, and orange plastic flip-off cap (Box of 1's)
Rx
Hikma Italia S.p.A.Italy
BSV Biosciences Phils., Inc.
DR-XY49583
Nov 14, 2031
TigilynTigecycline
50 mg Lyophilized Powder for Injection (IV)5 mL USP Type I Tubular Glass Vial (Box of 1's)
Rx
Lyka Labs LimitedIndia
BSV Bioscience Phils. Inc.Importer: Ambica International Corporation
DRP-6141
May 6, 2030
Tigycord 50Tigecycline
50 mg Lyophilized Powder for Solution for I.V. Infusion10 mL-Capacity USP Type I Clear and Colorless Glass Vial with Grey Rubber Stopper and Aluminum Seal with Orange Plastic Flip-Off Cap (Box of 1's)
Rx
Intas Pharmaceuticals LimitedIndia
Accord Healthcare Limited - Philippine Branch OfficeImporter: Accord Healthcare Limited-Philippine Branch Office
DRP-11512
Apr 1, 2027
TygacilTigecycline
50 mg Lyophilized Powder for Injection (IV Infusion)5 mL Type I Clear Glass Vial (Box of 1's)
Rx
Wyeth Lederle S.R.I.Italy
Importer: Pfizer, Inc.
DR-XY31516
Jan 27, 2027
TygacilTigecycline
50 mg Lyophilized Powder for Injection (IV Infusion)Type I Clear Glass Vial x 5 mL with Orange Flip-off Seal Box of 1's; Physician's sample: Type I Clear Glass Vial x 5 mL with Orange Flip-off Seal Box of 1's
Rx
Patheon Italia S.p.A.Italy
Importer: Pfizer, Inc.
DR-XY39444
May 16, 2029
TygepolTigecycline
50 mg Lyophilized Powder for Solution for I.V. Infusion5 mL-Capacity USP Type I Clear and Colorless Glass Vial with Bromobutyl Rubber Stopper and Aluminum Seal with Orange Flip-Off Cap (Box of 10's)
Rx
Aroma Ilac San. Ltd. Sti.Turkey
Stangen Pharmaceuticals Philippines, Inc.Trader: Polifarma Ilac Sanayi ve Ticaret A.S.
DRP-11650
Apr 6, 2027
TylinTigecycline
50 mg Lyophilized Powder for Injection for Intravenous (IV) InfusionUSP Type I Clear Glass Vial x 10 mL (Box of 1's)
Rx
Gufic Biosciences LimitedIndia
Medethix, Inc.
DRP-12819
Oct 10, 2027
ZytiglineTigecycline
50 mg Lyophilized Powder for Injection (I.V. Infusion)10 mL USP Type I clear glass vial, with grey butyl rubber stopper, aluminum seal and green-flip-off cap (Box of 5's)
Rx
United Biotech Pvt. Ltd.India
Despina Pharma Inc.
DRP-15921
Oct 1, 2029

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS For Injection: Each single-dose 10 mL glass vial contain 50 mg of tigecycline as an orange lyophilized powder for reconstitution. For Injection: 50 mg, lyophilized powder for reconstitution in a single-dose 10 mL vial. (3)

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label
  • • All-Cause Mortality: A meta-analysis of Phase 3 and 4 clinical trials demonstrated an increase in all-cause mortality in TYGACIL-treated patients compared to controls with a risk difference of 0.6% (95% CI 0.1, 1.2). The cause of this increase has not been established. An increase was also seen in a meta-analysis limited to the approved indications [0.6% (95% CI 0.0, 1.2)]. The greatest difference in mortality was seen in TYGACIL-treated patients with ventilator-associated pneumonia. (5.1, 5.2)
  • • Anaphylactic Reactions: have been reported with TYGACIL, and may be life-threatening. Avoid use in patients with known hypersensitivity to tetracyclines. (5.3)
  • • Hepatic Adverse Effects: have been reported with TYGACIL. Patients who develop abnormal liver function tests during TYGACIL therapy should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing tigecycline therapy. (5.4)
  • • Pancreatitis: including fatalities, has been reported with TYGACIL. If pancreatitis is suspected, then consider stopping TYGACIL. (5.5)
  • • Monitoring Blood Coagulation Parameters: Hypofibrinogenemia has been reported with TYGACIL. Monitor blood coagulation parameters, including fibrinogen, at baseline and regularly during treatment with TYGACIL. (5.6)
  • • Tooth Discoloration and Enamel Hypoplasia: The use of TYGACIL during tooth development (last …
5.1 All-Cause Mortality

5.1 All-Cause Mortality An increase in all-cause mortality has been observed in a meta-analysis of Phase 3 and 4 clinical trials in TYGACIL-treated patients versus comparator-treated patients. In all 13 Phase 3 and 4 trials that included a comparator, death occurred in 4.0% (150/3788) of patients receiving TYGACIL and 3.0% (110/3646) of patients receiving comparator drugs.

In a pooled analysis of these trials, based on a random effects model by trial weight, the adjusted risk difference of all-cause mortality was 0.6% (95% CI 0.1, 1.2) between TYGACIL and comparator-treated patients. An analysis of mortality in all trials conducted for approved indications (cSSSI, cIAI, and CABP), including post-market trials showed an adjusted mortality rate of 2.5% (66/2640) for tigecycline and 1.8% (48/2628) for comparator, respectively.

The adjusted risk difference for mortality stratified by trial weight was 0.6% (95% CI 0.0, 1.2). The cause of this mortality difference has not been established. Generally, deaths were the result of worsening infection, complications of infection or underlying co-morbidities. TYGACIL should be reserved for use in situations when alternative treatments are not suitable [see Boxed Warning, Indications and Usage (1.4), Warnings and Precautions (5.2) and Adverse Reactions (6.1)].

5.2 Mortality Imbalance and Lower Cure Rates in Hospital-Acquired Pneumonia

5.2 Mortality Imbalance and Lower Cure Rates in Hospital-Acquired Pneumonia A trial of patients with hospital acquired, including ventilator-associated, pneumonia failed to demonstrate the efficacy of TYGACIL. In this trial, patients were randomized to receive TYGACIL (100 mg initially, then 50 mg every 12 hours) or a comparator.

In addition, patients were allowed to receive specified adjunctive therapies. The sub-group of patients with ventilator-associated pneumonia who received TYGACIL had lower cure rates (47.9% versus 70.1% for the clinically evaluable population). In this trial, greater mortality was seen in patients with ventilator-associated pneumonia who received TYGACIL (25/131 [19.1%] versus 15/122 [12.3%] in comparator-treated patients) [see Adverse Reactions (6.1)].

Particularly high mortality was seen among TYGACIL-treated patients with ventilator-associated pneumonia and bacteremia at baseline (9/18 [50.0%] versus 1/13 [7.7%] in comparator-treated patients).

5.3 Anaphylactic Reactions

5.3 Anaphylactic Reactions Anaphylactic reactions have been reported with nearly all antibacterial agents, including TYGACIL, and may be life-threatening. TYGACIL is structurally similar to tetracycline-class antibacterial drugs and should be avoided in patients with known hypersensitivity to tetracycline-class antibacterial drugs.

5.4 Hepatic Adverse Effects

5.4 Hepatic Adverse Effects Increases in total bilirubin concentration, prothrombin time and transaminases have been seen in patients treated with tigecycline. Isolated cases of significant hepatic dysfunction and hepatic failure have been reported in patients being treated with tigecycline. Some of these patients were receiving multiple concomitant medications.

Patients who develop abnormal liver function tests during tigecycline therapy should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing tigecycline therapy. Hepatic dysfunction may occur after the drug has been discontinued.

5.5 Pancreatitis

5.5 Pancreatitis Acute pancreatitis, including fatal cases, has occurred in association with tigecycline treatment. The diagnosis of acute pancreatitis should be considered in patients taking tigecycline who develop clinical symptoms, signs, or laboratory abnormalities suggestive of acute pancreatitis. Cases have been reported in patients without known risk factors for pancreatitis.

Patients usually improve after tigecycline discontinuation. Consideration should be given to the cessation of the treatment with tigecycline in cases suspected of having developed pancreatitis [see Adverse Reactions (6.2)].

5.6 Monitoring of Blood Coagulation Parameters

5.6 Monitoring of Blood Coagulation Parameters Hypofibrinogenemia has been reported in patients treated with TYGACIL [see Adverse Reactions (6.2)]. Obtain baseline blood coagulation parameters, including fibrinogen, and continue to monitor regularly during treatment with TYGACIL.

5.7 Tooth Discoloration and Enamel Hypoplasia

5.7 Tooth Discoloration and Enamel Hypoplasia The use of TYGACIL during tooth development (last half of pregnancy, infancy, and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). This adverse reaction is more common during long-term use of tetracyclines, but it has been observed following repeated short-term courses.

Enamel hypoplasia has also been reported. Advise the patient of the potential risk to the fetus if TYGACIL is used during the second or third trimester of pregnancy [see Use in Specific Populations (8.1, 8.4)].

5.8 Inhibition of Bone Growth

5.8 Inhibition of Bone Growth The use of TYGACIL during the second and third trimester of pregnancy, infancy and childhood up to the age of 8 years may cause reversible inhibition of bone growth. All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in fibula growth rate has been observed in premature infants given oral tetracycline in doses of 25 mg/kg every 6 hours.

This reaction was shown to be reversible when the tetracycline was discontinued. Advise the patient of the potential risk to the fetus if TYGACIL is used during the second or third trimester of pregnancy [see Use in Specific Populations (8.1, 8.4)].

5.9 Clostridioides difficile

5.9 Clostridioides difficile -Associated Diarrhea Clostridioides difficile -associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including TYGACIL, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use.

Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

5.10 Sepsis/Septic Shock in Patients With Intestinal Perforation

5.10 Sepsis/Septic Shock in Patients With Intestinal Perforation Monotherapy with tigecycline should be avoided in patients with complicated intra-abdominal infections (cIAI) secondary to clinically apparent intestinal perforation. In cIAI studies (n=1642), 6 patients treated with TYGACIL and 2 patients treated with imipenem/cilastatin presented with intestinal perforations and developed sepsis/septic shock.

The 6 patients treated with TYGACIL had higher APACHE II scores (median = 13) versus the 2 patients treated with imipenem/cilastatin (APACHE II scores = 4 and 6). Due to differences in baseline APACHE II scores between treatment groups and small overall numbers, the relationship of this outcome to treatment cannot be established.

5.11 Tetracycline-Class Adverse Effects

5.11 Tetracycline-Class Adverse Effects TYGACIL is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse effects. Such effects may include: photosensitivity, fixed drug eruption, pseudotumor cerebri, and anti-anabolic action (which has led to increased BUN, azotemia, acidosis, and hyperphosphatemia).

Discontinue TYGACIL if any of these adverse reactions are suspected.

5.12 Development of Drug-Resistant Bacteria Prescribing

5.12 Development of Drug-Resistant Bacteria Prescribing TYGACIL in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Drug interactions

Drug or classSeverityEffectWhat to do
WarfarinAdjust or monitorChanged anticoagulant effect (label).Monitor PT/INR.
Tacrolimus, cyclosporineAdjust or monitorHigher calcineurin inhibitor levels; toxicity risk (label).Monitor levels.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed
Drug interactions (US label) US FDA label
  • • Warfarin: Suitable anticoagulation test should be monitored if TYGACIL is administered to patients receiving warfarin. (7.1)
  • • Calcineurin Inhibitors: Serum concentrations of calcineurin inhibitors (e.g., tacrolimus, cyclosporine) should be monitored during treatment with TYGACIL due to risk of toxicity. (7.2)
7.1 Warfarin

7.1 Warfarin Prothrombin time or other suitable anticoagulation test should be monitored if TYGACIL is administered with warfarin [see Clinical Pharmacology (12.3)].

7.2 Calcineurin Inhibitors

7.2 Calcineurin Inhibitors Concomitant use of TYGACIL and calcineurin inhibitors such as tacrolimus or cyclosporine may lead to an increase in serum trough concentrations of the calcineurin inhibitors. Therefore, serum concentrations of the calcineurin inhibitor should be monitored during treatment with TYGACIL to avoid drug toxicity.

7.3 Oral Contraceptives

7.3 Oral Contraceptives Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective.

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

In healthy male volunteers receiving 14 C-tigecycline, tigecycline was the primary 14 C-labeled material recovered in urine and feces, but a glucuronide, an N-acetyl metabolite, and a tigecycline epimer (each at no more than 10% of the administered dose) were also present.

Tigecycline is a substrate of P-glycoprotein (P-gp) based on an in vitro study using a cell line overexpressing P-gp.

The potential contribution of P-gp-mediated transport to the in vivo disposition of tigecycline is not known.

In addition, because tigecycline is not extensively metabolized, clearance of tigecycline is not expected to be affected by drugs that inhibit or induce the activity of these CYP450 isoforms.

In vitro studies using Caco-2 cells indicate that tigecycline does not inhibit digoxin flux, suggesting that tigecycline is not a P-glycoprotein (P-gp) inhibitor.

Tigecycline is a substrate of P-gp based on an in vitro study using a cell line overexpressing P-gp.

Coadministration of P-gp inhibitors (e.g., ketoconazole or cyclosporine) or P-gp inducers (e.g., rifampicin) could affect the pharmacokinetics of tigecycline.

Adverse reactions

Common

  • Nausea, vomiting, diarrhea, abdominal pain
  • Headache, raised ALT

Serious

  • Higher all-cause mortality (boxed warning)
  • Hepatotoxicity
  • Pancreatitis
  • Coagulopathy and low fibrinogen
  • Anaphylaxis
  • Clostridioides difficile-associated diarrhea
renalcarematters.com, reviewed
Adverse reactions (US label) US FDA label
  • The following serious adverse reactions are described elsewhere in the labeling: • All-Cause Mortality [see Boxed Warning and Warnings and Precautions (5.1)] • Mortality Imbalance and Lower Cure Rates in Hospital-Acquired Pneumonia [see Warnings and Precautions (5.2)] • Anaphylaxis [Warning and Precautions (5.3)] • Hepatic Adverse Effects [Warnings and Precautions (5.4)] • Pancreatitis [Warnings and Precautions (5.5)] The most common adverse reactions (incidence >5%) are nausea, vomiting, diarrhea, abdominal pain, headache, and increased SGPT. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In clinical trials, 2514 patients were treated with TYGACIL.

TYGACIL was discontinued due to adverse reactions in 7% of patients compared to 6% for all comparators. Table 1 shows the incidence of adverse reactions through test of cure reported in ≥2% of patients in these trials. Table 1. Incidence (%) of Adverse Reactions Through Test of Cure Reported in ≥ 2% of Patients Treated in Clinical Studies Body System Adverse Reactions TYGACIL (N=2514) Comparators Vancomycin/Aztreonam, Imipenem/Cilastatin, Levofloxacin, Linezolid.

(N=2307) Body as a Whole Abdominal pain 6 4 Abscess 2 2 Asthenia 3 2 Headache 6 7 Infection 7 5 Cardiovascular System Phlebitis 3 4 Digestive System Diarrhea 12 11 Dyspepsia 2 2 Nausea 26 13 Vomiting 18 9 Hemic and Lymphatic System Anemia 5 6 Metabolic and Nutritional Alkaline Phosphatase Increased 3 3 Amylase Increased 3 2 Bilirubinemia 2 1 BUN Increased 3 1 Healing Abnormal 3 2 Hyponatremia 2 1 Hypoproteinemia 5 3 SGOT Increased LFT abnormalities in TYGACIL-treated patients were reported more frequently in the post therapy period than those in comparator-treated patients, which occurred more often on therapy. 4 5 SGPT Increased 5 5 Respiratory System Pneumonia 2 2 Nervous System Dizziness 3 3 Skin and Appendages Rash 3 4 In all 13 Phase 3 and 4 trials that included a comparator, death occurred in 4.0% (150/3788) of patients receiving TYGACIL and 3.0% (110/3646) of patients receiving comparator drugs. In a pooled analysis of these trials, based on a random effects model by trial weight, an adjusted risk difference of all-cause mortality was 0.6% (95% CI 0.1, 1.2) between TYGACIL and comparator-treated patients (see Table 2).

The cause of the imbalance has not been established. Generally, deaths were the result of worsening infection, complications of infection or underlying co-morbidities. Table 2. Patients with Outcome of Death by Infection Type TYGACIL Comparator Risk Difference The difference between the percentage of patients who died in TYGACIL and comparator treatment groups.

The 95% CI for each infection type was calculated using the normal approximation method without continuity correction. Infection Type n/N % n/N % % (95% CI) CAP = Community-acquired pneumonia; cIAI = Complicated intra-abdominal infections; cSSSI = Complicated skin and skin structure infections; HAP = Hospital-acquired pneumonia; VAP = Ventilator-associated pneumonia; RP = Resistant pathogens; DFI = Diabetic foot infections.

Note: The studies include 300, 305, 900 (cSSSI), 301, 306, 315, 316, 400 (cIAI), 308 and 313 (CAP), 311 (HAP), 307 [Resistant gram-positive pathogen study in patients with MRSA or Vancomycin-Resistant Enterococcus (VRE)], and 319 (DFI with and without osteomyelitis). cSSSI 12/834 1.4 6/813 0.7 0.7 (-0.3, 1.7) cIAI 42/1382 3.0 31/1393 2.2 0.8 (-0.4, 2.0) CAP 12/424 2.8 11/422 2.6 0.2 (-2.0, 2.4) HAP 66/467 14.1 57/467 12.2 1.9 (-2.4, 6.3) Non-VAP These are subgroups of the HAP population. 41/336 12.2 42/345 12.2 0.0 (-4.9, 4.9) VAP 25/131 19.1 15/122 12.3 6.8 (-2.1, 15.7) RP 11/128 8.6 2/43 4.7 3.9 (-4.0, 11.9) DFI 7/553 1.3 3/508 0.6 0.7 (-0.5, 1.8) Overall Adjusted 150/3788 4.0 110/3646 3.0 0.6 (0.1, 1.2) Overall adjusted (random effects model by trial weight) risk difference estimate and 95% CI. An analysis of mortality in all trials conducted for approved indications - cSSSI, cIAI, and CABP, including post-market trials (one in cSSSI and two in cIAI) - showed an adjusted mortality rate of 2.5% (66/2640) for tigecycline and 1.8% (48/2628) for comparator, respectively.

The adjusted risk difference for mortality stratified by trial weight was 0.6% (95% CI 0.0, 1.2). In comparative clinical studies, infection-related serious adverse reactions were more frequently reported for subjects treated with TYGACIL (7%) versus comparators (6%). Serious adverse reactions of sepsis/septic shock were more frequently reported for subjects treated with TYGACIL (2%) versus comparators (1%).

Due to baseline differences between treatment groups in this subset of patients, the relationship of this outcome to treatment cannot be established [see Warnings and Precautions (5.10)]. The most common adverse reactions were nausea and vomiting which generally occurred during the first 1 – 2 days of therapy. The majority of cases of nausea and vomiting associated with TYGACIL and comparators were either mild or moderate in severity.

In patients treated with TYGACIL, nausea incidence was 26% (17% mild, 8% moderate, 1% severe) and vomiting incidence was 18% (11% mild, 6% moderate, 1% severe). In patients treated for complicated skin and skin structure infections (cSSSI), nausea incidence was 35% for TYGACIL and 9% for vancomycin/aztreonam; vomiting incidence was 20% for TYGACIL and 4% for vancomycin/aztreonam.

In patients treated for complicated intra-abdominal infections (cIAI), nausea incidence was 25% for TYGACIL and 21% for imipenem/cilastatin; vomiting incidence was 20% for TYGACIL and 15% for imipenem/cilastatin. In patients treated for community-acquired bacterial pneumonia (CABP), nausea incidence was 24% for TYGACIL and 8% for levofloxacin; vomiting incidence was 16% for TYGACIL and 6% for levofloxacin.

Discontinuation from TYGACIL was most frequently associated with nausea (1%) and vomiting (1%). For comparators, discontinuation was most frequently associated with nausea (<1%). The following adverse reactions were reported (<2%) in patients receiving TYGACIL in clinical studies: Body as a Whole: injection site inflammation, injection site pain, injection site reaction, septic shock, allergic reaction, chills, injection site edema, injection site phlebitis Cardiovascular System: thrombophlebitis Digestive System: anorexia, jaundice, abnormal stools Metabolic/Nutritional System: increased creatinine, hypocalcemia, hypoglycemia Special Senses: taste perversion Hemic and Lymphatic System: prolonged activated partial thromboplastin time (aPTT), prolonged prothrombin time (PT), eosinophilia, increased international normalized ratio (INR), thrombocytopenia Skin and Appendages: pruritus Urogenital System: vaginal moniliasis, vaginitis, leukorrhea

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of TYGACIL. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish causal relationship to drug exposure.

  • anaphylactic reactions
  • acute pancreatitis
  • hepatic cholestasis, and jaundice
  • severe skin reactions, including Stevens-Johnson Syndrome
  • symptomatic hypoglycemia in patients with and without diabetes mellitus
  • hypofibrinogenemia [see Warnings and Precautions (5.6)]
Adverse reaction frequency tables (US label) US FDA label
Table 1. Incidence (%) of Adverse Reactions Through Test of Cure Reported in ≥ 2% of Patients Treated in Clinical Studies
Body System Adverse ReactionsTYGACIL (N=2514)ComparatorsVancomycin/Aztreonam, Imipenem/Cilastatin, Levofloxacin, Linezolid. (N=2307)
Body as a Whole
Abdominal pain64
Abscess22
Asthenia32
Headache67
Infection75
Cardiovascular System
Phlebitis34
Digestive System
Diarrhea1211
Dyspepsia22
Nausea2613
Vomiting189
Hemic and Lymphatic System
Anemia56
Metabolic and Nutritional
Alkaline Phosphatase Increased33
Amylase Increased32
Bilirubinemia21
BUN Increased31
Healing Abnormal32
Hyponatremia21
Hypoproteinemia53
SGOT IncreasedLFT abnormalities in TYGACIL-treated patients were reported more frequently in the post therapy period than those in comparator-treated patients, which occurred more often on therapy.45
SGPT Increased55
Respiratory System
Pneumonia22
Nervous System
Dizziness33
Skin and Appendages
Rash34
Table 2. Patients with Outcome of Death by Infection Type
TYGACILComparatorRisk DifferenceThe difference between the percentage of patients who died in TYGACIL and comparator treatment groups. The 95% CI for each infection type was calculated using the normal approximation method without continuity correction.
Infection Typen/N%n/N%% (95% CI)
CAP = Community-acquired pneumonia; cIAI = Complicated intra-abdominal infections; cSSSI = Complicated skin and skin structure infections; HAP = Hospital-acquired pneumonia; VAP = Ventilator-associated pneumonia; RP = Resistant pathogens; DFI = Diabetic foot infections. Note: The studies include 300, 305, 900 (cSSSI), 301, 306, 315, 316, 400 (cIAI), 308 and 313 (CAP), 311 (HAP), 307 [Resistant gram-positive pathogen study in patients with MRSA or Vancomycin-Resistant Enterococcus (VRE)], and 319 (DFI with and without osteomyelitis).
cSSSI12/8341.46/8130.70.7 (-0.3, 1.7)
cIAI42/13823.031/13932.20.8 (-0.4, 2.0)
CAP12/4242.811/4222.60.2 (-2.0, 2.4)
HAP66/46714.157/46712.21.9 (-2.4, 6.3)
Non-VAPThese are subgroups of the HAP population. 41/33612.242/34512.20.0 (-4.9, 4.9)
VAP25/13119.115/12212.36.8 (-2.1, 15.7)
RP11/1288.62/434.73.9 (-4.0, 11.9)
DFI7/5531.33/5080.60.7 (-0.5, 1.8)
Overall Adjusted150/37884.0110/36463.00.6 (0.1, 1.2)Overall adjusted (random effects model by trial weight) risk difference estimate and 95% CI.

Monitoring parameters

  • Coagulation tests including fibrinogen at baseline and regularly; liver tests; pancreatitis symptoms (label). Kidney
  • Coagulation tests and fibrinogen
  • Liver tests
renalcarematters.com, reviewed

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary TYGACIL, like other tetracycline class antibacterial drugs, may cause permanent discoloration of deciduous teeth and reversible inhibition of bone growth when administered during the second and third trimesters of pregnancy [see Warnings and Precautions (5.7, 5.8), Data, and Use in Specific Populations (8.4)]. There are no available data on the risk of major birth defects or miscarriage following the use of TYGACIL during pregnancy.

Administration of intravenous tigecycline in pregnant rats and rabbits during the period of organogenesis was associated with reduction in fetal weights and an increased incidence of skeletal anomalies (delays in bone ossification) at exposures of 5 and 1 times the human exposure at the recommended clinical dose in rats and rabbits, respectively. Advise the patient of the potential risk to the fetus if TYGACIL is used during the second or third trimester.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U. S. general population, the estimated background risk in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Data Human Data The use of tetracycline-class antibacterial drugs, that includes TYGACIL, during tooth development (second and third trimester of pregnancy) may cause permanent discoloration of deciduous teeth. This adverse reaction is more common during long-term use of tetracyclines but has been observed following repeated short-term courses.

TYGACIL may cause reversible inhibition of bone growth when administered during the second and third trimesters of pregnancy. A decrease in fibula growth rate has been observed in premature infants given oral tetracycline in doses of 25 mg/kg every 6 hours. Animal Data In embryo-fetal development studies, tigecycline was administered during the period of organogenesis at doses up to 12 mg/kg/day in rats and 4 mg/kg in rabbits or 5 and 1 times the systemic exposure at the recommended clinical dose, respectively.

In the rat study, decreased fetal weight and fetal skeletal variations (reduced ossification of the pubic, ischial, and supraoccipital bones and increased incidences of rudimentary 14 th rib) were observed in the presence of maternal toxicity at 12 mg/kg/day (5 times the recommended clinical dose based on systemic exposure). In rabbits, decreased fetal weights were observed in the presence of maternal toxicity at 4 mg/kg (equivalent to the human exposure at the recommended clinical dose).

In preclinical safety studies, 14 C-labeled tigecycline crossed the placenta and was found in fetal tissues.

Mechanism of action

12.1 Mechanism of Action Tigecycline is a tetracycline class antibacterial [see Microbiology (12.4)].

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Cardiac Electrophysiology No significant effect of a single intravenous dose of TYGACIL 50 mg or 200 mg on QTc interval was detected in a randomized, placebo- and active-controlled four-arm crossover thorough QTc study of 46 healthy subjects.

Pharmacokinetics

Key PK parameters

Half-lifeAbout 27 hours (single dose); 42 hours (multiple doses)
Half-life in kidney failure (ESKD) kidneyNot significantly altered (label)
Volume of distributionAbout 570 to 640 L
Protein binding71% to 89%
Metabolism (CYP, transporters)Glucuronidation (minor)
Renal excretion kidneyAbout 22% unchanged in urine; 59% biliary/fecal
Dialyzability kidneyNo (label)
renalcarematters.com, reviewed
Half-life and elimination (verbatim, US label)

Excretion The recovery of total radioactivity in feces and urine following administration of 14 C-tigecycline indicates that 59% of the dose is eliminated by biliary/fecal excretion, and 33% is excreted in urine.

Approximately 22% of the total dose is excreted as unchanged tigecycline in urine.

Overall, the primary route of elimination for tigecycline is biliary excretion of unchanged tigecycline and its metabolites.

Glucuronidation and renal excretion of unchanged tigecycline are secondary routes.

However, systemic clearance of tigecycline was reduced by 25% and the half-life of tigecycline was prolonged by 23% in patients with moderate hepatic impairment (Child Pugh B).

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics The mean pharmacokinetic parameters of tigecycline after single and multiple intravenous doses based on pooled data from clinical pharmacology studies are summarized in Table 3. Intravenous infusions of tigecycline were administered over approximately 30 to 60 minutes. Table 3. Mean (CV%) Pharmacokinetic Parameters of Tigecycline Single Dose 100 mg (N=224) Multiple Dose 100 mg initially, followed by 50 mg every 12 hours 50 mg every 12h (N=103) C max (mcg/mL) 30-minute infusion 1.45 (22%) 0.87 (27%) C max (mcg/mL) 60-minute infusion 0.90 (30%) 0.63 (15%) AUC (mcg∙h/mL) 5.19 (36%) - - AUC 0–24h (mcg∙h/mL) - - 4.70 (36%) C min (mcg/mL) - - 0.13 (59%) t ½ (h) 27.1 (53%) 42.4 (83%) CL (L/h) 21.8 (40%) 23.8 (33%) CL r (mL/min) 38.0 (82%) 51.0 (58%) V ss (L) 568 (43%) 639 (48%) Distribution The in vitro plasma protein binding of tigecycline ranges from approximately 71% to 89% at concentrations observed in clinical studies (0.1 to 1.0 mcg/mL).

The steady-state volume of distribution of tigecycline averaged 500 to 700 L (7 to 9 L/kg), indicating tigecycline is extensively distributed beyond the plasma volume and into the tissues. Following the administration of tigecycline 100 mg followed by 50 mg every 12 hours to 33 healthy volunteers, the tigecycline AUC 0–12h (134 mcg∙h/mL) in alveolar cells was approximately 78-fold higher than the AUC 0–12h in the serum, and the AUC 0–12h (2.28 mcg∙h/mL) in epithelial lining fluid was approximately 32% higher than the AUC 0–12h in serum.

The AUC 0–12h (1.61 mcg∙h/mL) of tigecycline in skin blister fluid was approximately 26% lower than the AUC 0–12h in the serum of 10 healthy subjects. In a single-dose study, tigecycline 100 mg was administered to subjects prior to undergoing elective surgery or medical procedure for tissue extraction. Concentrations at 4 hours after tigecycline administration were higher in gallbladder (38-fold, n=6), lung (3.7-fold, n=5), and colon (2.3-fold, n=6), and lower in synovial fluid (0.58-fold, n=5), and bone (0.35-fold, n=6) relative to serum.

The concentration of tigecycline in these tissues after multiple doses has not been studied. Elimination Metabolism Tigecycline is not extensively metabolized. In vitro studies with tigecycline using human liver microsomes, liver slices, and hepatocytes led to the formation of only trace amounts of metabolites. In healthy male volunteers receiving 14 C-tigecycline, tigecycline was the primary 14 C-labeled material recovered in urine and feces, but a glucuronide, an N-acetyl metabolite, and a tigecycline epimer (each at no more than 10% of the administered dose) were also present.

Tigecycline is a substrate of P-glycoprotein (P-gp) based on an in vitro study using a cell line overexpressing P-gp. The potential contribution of P-gp-mediated transport to the in vivo disposition of tigecycline is not known. Excretion The recovery of total radioactivity in feces and urine following administration of 14 C-tigecycline indicates that 59% of the dose is eliminated by biliary/fecal excretion, and 33% is excreted in urine.

Approximately 22% of the total dose is excreted as unchanged tigecycline in urine. Overall, the primary route of elimination for tigecycline is biliary excretion of unchanged tigecycline and its metabolites. Glucuronidation and renal excretion of unchanged tigecycline are secondary routes. Specific Populations Hepatic Impairment In a study comparing 10 patients with mild hepatic impairment (Child Pugh A), 10 patients with moderate hepatic impairment (Child Pugh B), and 5 patients with severe hepatic impairment (Child Pugh C) to 23 age and weight matched healthy control subjects, the single-dose pharmacokinetic disposition of tigecycline was not altered in patients with mild hepatic impairment.

However, systemic clearance of tigecycline was reduced by 25% and the half-life of tigecycline was prolonged by 23% in patients with moderate hepatic impairment (Child Pugh B). Systemic clearance of tigecycline was reduced by 55%, and the half-life of tigecycline was prolonged by 43% in patients with severe hepatic impairment (Child Pugh C).

Dosage adjustment is necessary in patients with severe hepatic impairment (Child Pugh C) [see Use in Specific Populations (8.6) and Dosage and Administration (2.2)]. Renal Impairment A single dose study compared 6 subjects with severe renal impairment (creatinine clearance <30 mL/min), 4 end stage renal disease (ESRD) patients receiving tigecycline 2 hours before hemodialysis, 4 ESRD patients receiving tigecycline 1 hour after hemodialysis, and 6 healthy control subjects.

The pharmacokinetic profile of tigecycline was not significantly altered in any of the renally impaired patient groups, nor was tigecycline removed by hemodialysis. No dosage adjustment of TYGACIL is necessary in patients with renal impairment or in patients undergoing hemodialysis. Geriatric Patients No significant differences in pharmacokinetics were observed between healthy elderly subjects (n=15, age 65–75; n=13, age >75) and younger subjects (n=18) receiving a single 100-mg dose of TYGACIL.

Therefore, no dosage adjustment is necessary based on age [see Use in Specific Populations (8.5)]. Pediatric Patients A single-dose safety, tolerability, and pharmacokinetic study of tigecycline in pediatric patients aged 8–16 years who recently recovered from infections was conducted. The doses administered were 0.5, 1, or 2 mg/kg.

The study showed that for children aged 12–16 years (n = 16) a dosage of 50 mg twice daily would likely result in exposures comparable to those observed in adults with the approved dosing regimen. Large variability observed in children aged 8 to 11 years of age (n = 8) required additional study to determine the appropriate dosage.

A subsequent tigecycline dose-finding study was conducted in 8–11 year old patients with cIAI, cSSSI, or CABP. The doses of tigecycline studied were 0.75 mg/kg (n = 17), 1 mg/kg (n = 21), and 1.25 mg/kg (n=20). This study showed that for children aged 8–11 years, a 1.2 mg/kg dose would likely result in exposures comparable to those observed in adults resulting with the approved dosing regimen [see Dosage and Administration (2.3)].

Gender In a pooled analysis of 38 women and 298 men participating in clinical pharmacology studies, there was no significant difference in the mean (±SD) tigecycline clearance between women (20.7±6.5 L/h) and men (22.8±8.7 L/h). Therefore, no dosage adjustment is necessary based on gender. Race In a pooled analysis of 73 Asian subjects, 53 Black subjects, 15 Hispanic subjects, 190 White subjects, and 3 subjects classified as "other" participating in clinical pharmacology studies, there was no significant difference in the mean (±SD) tigecycline clearance among the Asian subjects (28.8±8.8 L/h), Black subjects (23.0±7.8 L/h), Hispanic subjects (24.3±6.5 L/h), White subjects (22.1±8.9 L/h), and "other" subjects (25.0±4.8 L/h).

Therefore, no dosage adjustment is necessary based on race. Drug Interaction Studies Digoxin TYGACIL (100 mg followed by 50 mg every 12 hours) and digoxin (0.5 mg followed by 0.25 mg, orally, every 24 hours) were co-administered to healthy subjects in a drug interaction study. Tigecycline slightly decreased the C max of digoxin by 13%, but did not affect the AUC or clearance of digoxin.

This small change in C max did not affect the steady-state pharmacodynamic effects of digoxin as measured by changes in ECG intervals. In addition, digoxin did not affect the pharmacokinetic profile of tigecycline. Therefore, no dosage adjustment of either drug is necessary when TYGACIL is administered with digoxin. Warfarin Concomitant administration of TYGACIL (100 mg followed by 50 mg every 12 hours) and warfarin (25 mg single-dose) to healthy subjects resulted in a decrease in clearance of R-warfarin and S-warfarin by 40% and 23%, an increase in C max by 38% and 43% and an increase in AUC by 68% and 29%, respectively.

Tigecycline did not significantly alter the effects of warfarin on INR. In addition, warfarin did not affect the pharmacokinetic profile of tigecycline. However, prothrombin time or other suitable anticoagulation test should be monitored if tigecycline is administered with warfarin. In vitro studies in human liver microsomes indicate that tigecycline does not inhibit metabolism mediated by any of the following 6 cytochrome P450 (CYP) isoforms: 1A2, 2C8, 2C9, 2C19, 2D6, and 3A4.

Therefore, TYGACIL is not expected to alter the metabolism of drugs metabolized by these enzymes. In addition, because tigecycline is not extensively metabolized, clearance of tigecycline is not expected to be affected by drugs that inhibit or induce the activity of these CYP450 isoforms. In vitro studies using Caco-2 cells indicate that tigecycline does not inhibit digoxin flux, suggesting that tigecycline is not a P-glycoprotein (P-gp) inhibitor.

This in vitro information is consistent with the lack of effect of tigecycline on digoxin clearance noted in the in vivo drug interaction study described above. Tigecycline is a substrate of P-gp based on an in vitro study using a cell line overexpressing P-gp. The potential contribution of P-gp-mediated transport to the in vivo disposition of tigecycline is not known.

Coadministration of P-gp inhibitors (e.g., ketoconazole or cyclosporine) or P-gp inducers (e.g., rifampicin) could affect the pharmacokinetics of tigecycline.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Tygacil · Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. [US FDA-approved label, version 50, November 18, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ccdb48e-c14a-4eeb-348c-4920ccfd7465
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. (2025). TYGACIL (tigecycline) for injection [Prescribing information; US FDA-approved label, NDA021821, set ID 2ccdb48e-c14a-4eeb-348c-4920ccfd7465, version effective November 18, 2025]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ccdb48e-c14a-4eeb-348c-4920ccfd7465
  4. Li, L., Li, X., Xia, Y., Chu, Y., Zhong, H., Li, J., Liang, P., Bu, Y., Zhao, R., Liao, Y., Yang, P., Lu, X., & Jiang, S. (2020). Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy. Frontiers in Pharmacology, 11, Article 786. https://doi.org/10.3389/fphar.2020.00786
  5. Li, P. K.-T., Chow, K. M., Cho, Y., Fan, S., Figueiredo, A. E., Harris, T., Kanjanabuch, T., Kim, Y.-L., Madero, M., Malyszko, J., Mehrotra, R., Okpechi, I. G., Perl, J., Piraino, B., Runnegar, N., Teitelbaum, I., Wong, J. K.-W., Yu, X., & Johnson, D. W. (2022). ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Peritoneal Dialysis International, 42(2), 110–153. https://doi.org/10.1177/08968608221080586

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .